Abstract:The high sensitivity of the pentagastrin stimulation test in detecting primary or metastatic medullary thyroid cancer (MTC) suggests a widespread expression of the corresponding receptor type on human MTC. Indeed, autoradiographic studies demonstrated cholecystokinin (CCK)-B/gastrin receptors not only in more than 90% of MTCs, but also in a high percentage of small-cell lung cancers, stromal ovarian tumors, and potentially a variety of other tumors, including gastrointestinal adenocarcinomas, neuroendocrine tumore, and malignant glioma. The aim of our work was to develop and systematically optimize suitable radioligands for targeting CCK-B receptors in vivo and to investigate their role in the staging and therapy of MTC and other CCK-B receptor-expressing malignancies. For this purpose, a variety of CCK/gastrin-related peptides, all having in common the C-terminal CCK-receptor binding tetrapeptide sequence-Trp-Met-Asp-PheNH2 or derivatives thereof, were investigated. They were members of the gastrin or cholecystokinin famillies or possessed characteristics of both, which differ by the intramolecular position of a tyrosyl moiety. Their stability and affinity were studied and optimized in vitro and in vivo; their biodistribution and therapeutic efficacy were tested in preclinical models. Best tumor uptake and tumor to nontumor ratios were obtained with members of the gastrin family, because of their superior selectivity and affinity for the CCK-B receptor subtype. Radiometal-labeled derivates of minigastrin showed excellent targeting of CCK-B receptor-expressing tissues in animals and healthy human volunteers. Preclinical therapy experiments in MTC-bearing animals showed significant antitumor efficacy. In a subsequent clinical study, 45 MTC patients with metastatic MTC were investigated; 23 had known and 22 had occult disease. CCK-B receptor scintigraphy was performed with 111In-diethylenetriamine pentaacetic acid-d-Glu1-minigastrin. The normal organ uptake was essentially confined to the stomach (and, to a lesser extent, to the gallbladder and, in premenopausal women, to normal breast tissue) as a result of CCK-B receptor-specific binding and to the kidneys, as excretory organs. All tumor manifestations known from conventional imaging were visualized as early as 1 hour postinjection, with increasing tumor to background ratios over time; at least 1 lesion was detected in 20 of 22 patients with occult disease (patient-based sensitivity, 91%). Among them were local recurrences and lymph node, pulmonary, hepatic, splenic, and bone (marrow) metastases. Eight patients with advanced metastatic disease were injected in a dose-escalation study with potentially therapeutic activities of a 90Y-labeled minigastrin derivative at 4 to 6-week intervals (30–50 mCi/m2 per injection for a maximum of 4 injections). Hematologic and renal toxicities were identified as the dose-limiting toxicities at the 40 and 50 mCi/m2 levels. Two patients experienced partial remissions, and 4 experienced stabilization of their previously rapidly progressing disease. These data suggest that CCK-B receptor ligands may be a useful new class of receptor-binding peptides for diagnosis and therapy of a variety of (CCK-B receptor-expressing) tumor types. They allow for sensitive and reliable staging of patients with metastatic MTC. Initial therapeutic results are promising, but nephrotoxicity is a major concern to be solved.

Study on the Receptor for Glycine-extended Gastrin on Colon and Colorectal Neoplasms

188Re-Labeled GX1 Dimer As a Novel Dual-Functional Probe Targeting TGM2 for Imaging and Antiangiogenic Therapy of Gastric Cancer

Identification of a 70-kDa gastrin-binding protein on DLD-1 human colorectal carcinoma cells.

<SUP>68</SUP>Ga-Labeled GX1 Dimer: A Novel Probe for PET/Cerenkov Imaging Targeting Gastric Cancer

Effect of Steroid on Binding Properties of Glycine Receptors on Synaptic Plasma Membrane from Rats

Both Glycine-Extended Gastrin (G-Gly) and Gastrin (G17) Stimulated COX-2 Expression Via CCK-B Receptor in Intestinal Epithelial Cells

Expression of gastrin receptor in tumors and its application as a molecular target for cancer diagnosis and therapy

THE EXPRESSION OF RECEPTORS FOR VASOACTIVE INTESTINAL PEPTIDE AND SECRETIN IN COLON NEOPLASMS

The Study of the Gastrin and the Expression of Its Receptor in Colorectal Cancer

Binding Effect of Fluorescence Labeled Glycyrrhetinic Acid with GA Receptors in Hepatocellular Carcinoma Cells.

Effect of Glycin-extended Gastrin on Human Gastric Cancer Cell Line SGC-7901 in Vitro

Relationship Betwent Surum Gastrin and the Expression of Gastrin in the Cancer Cell with the Clinical Behavior of Patients with Colorectal Carcinoma Cancer

The selection and characterization of the peptides binding to the cells and tissues of gastric carcinoma

Screening and Characterization of Multipeptide Binding Specifically to Gastric Cancer Cells by Phage Peptide Library

Experiment Study on the Competition for the Cell Receptor of Gastric Cancer and Normal Cells with Luteinizing Hormone-Releasing Hormone and Aeruginosa Exotoxin 40

Cholecystokinin-A and Cholecystokinin-B Gastrin Receptor Mrna Expression in the Gastrointestinal Tract and Pancreas of the Rat and Man - A Polymerase Chain Reaction Study

The Characteristics of Gastrin Receptor Expression in Gastric Cancer

Coexpression of Cholecystokinin-B/gastrin Receptor and Gastrin Gene in Human Gastric Tissues and Gastric Cancer Cell Line

Investigation and Characterization of Receptors for Pituitary Adenylate Cyclase Activating Polypeptide in Human Gastric Cancer Cell Line by Radioligand Binding

Growth Hormone Receptor Expression in the Rat Gastrointestinal Tract

Screening and identification of CD44v9 specific peptide ligand for gastric cancer detection